Though crowded, the identity management market seems eager for new solutions, and Venice is finding traction.

IV drips promising boosted wellbeing are gaining popularity, but are they worth it? We speak to the experts to find out.

A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. | A new entrant in the race to shepherd antibodies for Alzheimer’s disease across ...

Lightsabers curling plasma, jetpacks for casual flights: My 15 top absurd picks from Star Wars to The Rocketeer show how ...

Coming up this week on Inside Valley Politics, Governor Abbott visits Harlingen for the Cameron County Republican Party’s ...

The fintech narrative has shifted. After years of consumer-facing growth stories, the industry's centre of gravity is moving ...

Finding Hope for Frizzle (FRRS1L), a parent-led nonprofit organization working to develop a lifesaving treatment for FRRS1L patients, and Apertura Gene Therapy, a biotechnology company developing next ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK ...

Health advocate network Solace Health gained unicorn status after closing a $130 million Series C funding round.

Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS ...

An investigation has concluded that a woman’s discharge from Wrexham Maelor Hospital was appropriate, despite her death later ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...